Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's ...

and lifestyle changes Chronic obstructive pulmonary disease, commonly referred to as COPD, is a group of progressive lung diseases. An estimated 32 million people in the United States have COPD.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Long-term health care utilization is greater among patients with COPD who have tested positive for COVID-19 and are unvaccinated.

Regeneron Pharmaceuticals declined by 16.7 percent last week as investors sold off positions amid the surprising failure of ...

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a study.

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

MD, CFPC, FCFP, Family Physician, discusses What is Chronic Obstructive Pulmonary Disease.